Cargando…

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival

Chronic lymphocytic leukemia (CLL) cells are highly dependent on microenvironmental cells and signals. The lymph node (LN) is the critical site of in vivo CLL proliferation and development of resistance to both chemotherapy and targeted agents. We present a new model that incorporates key aspects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haselager, Marco V., van Driel, Bianca F., Perelaer, Eduard, de Rooij, Dennis, Lashgari, Danial, Loos, Remco, Kater, Arnon P., Moerland, Perry D., Eldering, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448932/ https://www.ncbi.nlm.nih.gov/pubmed/37637994 http://dx.doi.org/10.1097/HS9.0000000000000938

Ejemplares similares

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

Functional Differences Between EBV- and CMV-Specific CD8(+) T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
por: Hofland, Tom, et al.
Publicado: (2020)

The Therapeutic Potential of Targeting NIK in B Cell Malignancies
por: Haselager, Marco V., et al.
Publicado: (2022)

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
por: Jacobs, Chaja F., et al.
Publicado: (2021)

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
por: van Attekum, Martijn HA, et al.
Publicado: (2017)

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
por: Collins, McKensie A., et al.
Publicado: (2022)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors
por: Martens, Anne W. J., et al.
Publicado: (2023)

SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma
por: Leeksma, Alexander C., et al.
Publicado: (2022)

A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors
por: Janssen, Jerry, et al.
Publicado: (2021)

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia
por: van Attekum, M H A, et al.
Publicado: (2017)

P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Montironi, Chiara, et al.
Publicado: (2023)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex
por: Maas, C, et al.
Publicado: (2013)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

OVCAR-3 Spheroid-Derived Cells Display Distinct Metabolic Profiles
por: Vermeersch, Kathleen A., et al.
Publicado: (2015)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
por: Kater, Arnon, et al.
Publicado: (2023)

P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Simon-Molas, Helga, et al.
Publicado: (2023)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
por: Hengeveld, Paul J., et al.
Publicado: (2023)

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production
por: Karabon, Lidia, et al.
Publicado: (2021)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

The APRIL paradox in normal versus malignant B cell biology
por: van Attekum, M H A, et al.
Publicado: (2016)

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling
por: van Attekum, MHA, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_90d21o4nqn4hoqcj1lh9k9sev2